PARIS and MARSEILLE, France, January 11 /PRNewswire-FirstCall/ -- The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain.

Affymetrix Inc. (Nasdaq: AFFX) today announced that its technology powers the Ipsogen MapQuant Dx(TM) Genomic Grade, the first genomic test designed to provide a more precise measurement of tumor grade than previous techniques.